Stay updated on Taldefgrobep Alfa in SMA Clinical Trial
Sign up to get notified when there's something new on the Taldefgrobep Alfa in SMA Clinical Trial page.

Latest updates to the Taldefgrobep Alfa in SMA Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 was removed from the page. This appears to be a non-functional update related to versioning rather than study details or user-facing content.SummaryDifference0.0%

- Check28 days agoChange DetectedThe page removes a general government funding/operational status notice; core trial details, eligibility criteria, and outcomes remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check43 days agoChange DetectedThe list of study locations has been expanded to include additional sites across multiple countries. This broadens participant access and informs how the trial is conducted.SummaryDifference0.3%

- Check71 days agoChange DetectedUpdated medical term from Proximal spinal muscular atrophy to spinal muscular atrophy and bumped revision to v3.2.0; added a government operations status notice. Removed the more specific term and previous version label.SummaryDifference4%

- Check79 days agoChange DetectedUpdated to Revision v3.1.0 and removal of multiple drug-safety topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs), indicating content pruning in the drug-safety area and a new version tag.SummaryDifference0.4%

- Check93 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing the previous v3.0.1, indicating a new release. The 'Back to Top' element has been removed.SummaryDifference0.2%

Stay in the know with updates to Taldefgrobep Alfa in SMA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Taldefgrobep Alfa in SMA Clinical Trial page.